Last reviewed · How we verify
NCT04080856: GRACE
Real-World Experience Study of Elagolix For the Treatment of Endometriosis in Canada
trial in Endometriosis in 100 participants. Completed in 27 September 2021.
27 September 2021
Quick facts
| Lead sponsor | AbbVie |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 4 December 2019 |
| Primary completion | 27 September 2021 |
| Estimated completion | 27 September 2021 |
| Sites | 18 locations across Canada |
Conditions studied
- Endometriosis — all drugs for Endometriosis →
Sponsor
AbbVie — full company profile →
Who can join
Adults 18 to 50, female only, with Endometriosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study is to evaluate real-world effectiveness of elagolix in Canadian women with endometriosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04080856
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometriosis
Currently open trials in the same condition.
- NCT06559852 — The Impact of Yoga on Endometriosis-Related Pain · NA · recruiting
- NCT07393295 — Efficacy and Tolerability of TENS in Endometriosis-related Pain · NA · recruiting
- NCT07134023 — Educational Program for the Multidisciplinary Support of Patients With Endometriosis · NA · recruiting
- NCT07240883 — ENDO1000 - A UK-wide Endometriosis Research Project · recruiting
- NCT06974773 — Remote Electrical Stimulation as a Long-term Intervention for Endometriosis Flare Ups · NA · recruiting
Other AbbVie trials
Trials by the same sponsor.
- NCT07219017 — A Study to Assess the Mass Balance of Oral ABBV-1354 in Healthy Adult Male Participants · Phase 1 · completed
- NCT05316220 — A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years W · Phase 3 · withdrawn
- NCT07024797 — Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult · Phase 1 · completed
- NCT07058051 — Cross-sectional Study to Characterize Real World Burden of Disease in Patients With Vitiligo in China · completed
- NCT07007091 — A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04080856 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AbbVie
- Last refreshed: 28 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04080856.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing